| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.20B | -12.5% |
| Gross profit | ¥0.03B | — |
| Operating income | ¥-0.00B | — |
| Net income | ¥-0.00B | -131.5% |
| Gross margin | 16.3% | Net margin -1.6% |
| Revenue Q/Q | -16.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.17B | 83.7% |
| R&D | ¥0.01B | 4.7% |
| SG&A | ¥0.02B | 11.3% |
| Tax & other | ¥0.00B | 0.3% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
广和通 ・ 凯普生物 ・ 德艺文创 ・ 正丹股份 ・ 透景生命 ・ 万通智控 ・ 南京聚隆 ・ 正元智慧 ・ 超频三 ・ 星云股份 ・ 杭州园林 ・ 太龙股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies